WO2023205738A3 - Orthogonal il-21 receptor/cytokine systems - Google Patents

Orthogonal il-21 receptor/cytokine systems Download PDF

Info

Publication number
WO2023205738A3
WO2023205738A3 PCT/US2023/066016 US2023066016W WO2023205738A3 WO 2023205738 A3 WO2023205738 A3 WO 2023205738A3 US 2023066016 W US2023066016 W US 2023066016W WO 2023205738 A3 WO2023205738 A3 WO 2023205738A3
Authority
WO
WIPO (PCT)
Prior art keywords
orthogonal
receptor
cytokine
ortho
receptors
Prior art date
Application number
PCT/US2023/066016
Other languages
French (fr)
Other versions
WO2023205738A2 (en
Inventor
Nigel Killeen
Oren BESKE
Benedikt K. VOLLRATH
Sridhar Govindarajan
Original Assignee
Neptune Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neptune Biosciences Llc filed Critical Neptune Biosciences Llc
Publication of WO2023205738A2 publication Critical patent/WO2023205738A2/en
Publication of WO2023205738A3 publication Critical patent/WO2023205738A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Abstract

Orthogonal IL-21 receptors and orthogonal IL-21 cytokines are described. The IL-21 receptor-cytokine pairs may include an orthogonal interleukin-21 receptor a chain ("ortho-IL- 21Ra") that has impaired binding to native interleukin-21 cytokine ("IL-21") and an orthogonal IL-21 cytokine ("ortho-IL-21") that has impaired binding to native IL-21Ra, wherein the ortho¬ IL-21Ra binds to the ortho-IL-21. The IL-21 receptor-cytokine pair may activate IL-21 signaling. Cells engineered to express the orthogonal IL-21 receptors are also described, as well as methods for using such cells for treatment of various diseases and disorders.
PCT/US2023/066016 2022-04-20 2023-04-20 Orthogonal il-21 receptor/cytokine systems WO2023205738A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263333090P 2022-04-20 2022-04-20
US202263333085P 2022-04-20 2022-04-20
US63/333,085 2022-04-20
US63/333,090 2022-04-20

Publications (2)

Publication Number Publication Date
WO2023205738A2 WO2023205738A2 (en) 2023-10-26
WO2023205738A3 true WO2023205738A3 (en) 2023-11-30

Family

ID=88420746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/066016 WO2023205738A2 (en) 2022-04-20 2023-04-20 Orthogonal il-21 receptor/cytokine systems

Country Status (1)

Country Link
WO (1) WO2023205738A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028316A1 (en) * 2017-08-03 2019-02-07 Amgen Inc. Interleukin-21 muteins and methods of treatment
WO2019246508A1 (en) * 2018-06-21 2019-12-26 Shattuck Labs, Inc. Heterodimeric proteins and uses thereof
WO2021253360A1 (en) * 2020-06-18 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028316A1 (en) * 2017-08-03 2019-02-07 Amgen Inc. Interleukin-21 muteins and methods of treatment
WO2019246508A1 (en) * 2018-06-21 2019-12-26 Shattuck Labs, Inc. Heterodimeric proteins and uses thereof
WO2021253360A1 (en) * 2020-06-18 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE UNIPROTKB ANONYMOUS : "G1RE48 · G1RE48_NOMLE", XP093116021, retrieved from UNIPROT *

Also Published As

Publication number Publication date
WO2023205738A2 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
AU2003268486A1 (en) Cancer therapy using whole glucan particles and antibodies
MY140767A (en) Compounds, methods and compositions
WO2003103575A3 (en) Compounds, compositions, and methods
MXPA06014465A (en) Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation.
WO2009061853A3 (en) Mutant interleukin-2 (il-2) polypeptides
EP1715884A4 (en) Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
MY140169A (en) Compounds, compositions, and methods
WO2004018058A3 (en) Compounds, compositions, and methods
TW200517126A (en) Mesothelioma therapeutic agent
MY169308A (en) Treatment of tnf? related disorders
MY161812A (en) Substituted imidazo ring systems and methods
SG167664A1 (en) 2,4-pyrimidinediamine compounds and their uses
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
WO2020057541A8 (en) Anti-ifnar1 antibodies for treating autoimmune diseases
WO2004009036A3 (en) Compounds compositions and methods
EP1589998A4 (en) Uses of mammalian cytokine; related reagents
PH12019502617A1 (en) Antibody-cytokine engrafted proteins and methods of use for immune related disorders
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
AU2003252025A1 (en) Compounds, compositions, and methods
CR20230259A (en) Heavy chain antibodies binding to folate receptor alpha
WO2023205738A3 (en) Orthogonal il-21 receptor/cytokine systems
WO2004110385A3 (en) Modulators of the glucocorticoid receptor and method
WO2004029214A8 (en) Lfa-1 alpha subunit antibodies and methods of use
MX2007004597A (en) Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation.
WO2004034972A3 (en) Compounds, compositions, and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23792786

Country of ref document: EP

Kind code of ref document: A2